Paths of Progress 2023
The articles below are featured in the 2023 issue of our Paths of Progress magazine. To see the entire publication, which includes Dana-Farber's 2022 Annual Report, please download the PDF version.
One Drug, Two Targets
Bispecific antibodies are new cancer drugs modeled after the body's own disease-fighting antibodies, but with a sort of superpower: They can bind to two different targets at one time.
Finding Pancreatic Cancer Earlier
How Dana-Farber is transforming the narrative in the early detection and treatment of a stubborn cancer.
The Power of Plus
Combining immunotherapy with other treatments shows great promise against certain cancers. Dana-Farber researchers are working to enhance its effectiveness, target more types of cancer, and lengthen remissions.
50 Years of Stem Cell Transplants
Five decades of scientific effort have made Dana-Farber a worldwide leader in stem cell transplants, transforming the lives of thousands of patients.
Request a Publication
Receive by mail the current issue of a Dana-Farber publication by completing this request form.
Media Contacts
If you are a journalist and have a question about any of our stories or need more information, email media@dfci.harvard.edu or call 617-632-4090 and ask to speak to a member of the media team.
The Media Team cannot respond to patient inquiries. For more information on contacting Dana-Farber, please see Contact Us.